These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 28373003

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K.
    Cancer Res; 2001 Feb 15; 61(4):1637-44. PubMed ID: 11245477
    [Abstract] [Full Text] [Related]

  • 6. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC.
    Prostate; 2008 Jan 01; 68(1):92-104. PubMed ID: 18008334
    [Abstract] [Full Text] [Related]

  • 7. Bone metastasis: can osteoclasts be excluded?
    Martin TJ, Mundy GR.
    Nature; 2007 Feb 22; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
    [Abstract] [Full Text] [Related]

  • 8. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
    Uehara H, Takahashi T, Izumi K.
    Int J Oncol; 2013 Aug 22; 43(2):365-74. PubMed ID: 23708710
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
    Wang J, Chen TY, Qin S, Duan Y, Wang G.
    Med Hypotheses; 2013 Nov 22; 81(5):805-6. PubMed ID: 24074896
    [Abstract] [Full Text] [Related]

  • 12. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A.
    J Exp Clin Cancer Res; 2019 Jan 08; 38(1):12. PubMed ID: 30621730
    [Abstract] [Full Text] [Related]

  • 13. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X, Liu Y, Wu B, Dong Z, Wang Y, Lu J, Shi P, Bai W, Wang Z.
    Oncol Rep; 2014 Dec 08; 32(6):2605-11. PubMed ID: 25333856
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC, Chaisson M.
    Cancer Metastasis Rev; 2006 Dec 08; 25(4):541-9. PubMed ID: 17180711
    [Abstract] [Full Text] [Related]

  • 17. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG.
    Anticancer Res; 2013 Jan 08; 33(1):199-206. PubMed ID: 23267146
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z, Xiao J, Wu X, Li W, Yang Z, Xie J, Xu L, Cai X, Lin Z, Guo W, Luo J, Liu M.
    Curr Mol Med; 2012 Sep 08; 12(8):967-81. PubMed ID: 22574935
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.